Q4 EPS Estimates for Globus Medical Reduced by Roth Capital

Globus Medical, Inc. (NYSE:GMED - Free Report) - Equities research analysts at Roth Capital dropped their Q4 2025 EPS estimates for shares of Globus Medical in a report issued on Wednesday, November 6th. Roth Capital analyst J. Wittes now forecasts that the medical device company will post earnings of $0.91 per share for the quarter, down from their prior forecast of $0.92. The consensus estimate for Globus Medical's current full-year earnings is $2.84 per share.

A number of other equities research analysts have also recently issued reports on the stock. Roth Mkm reaffirmed a "buy" rating and issued a $100.00 price objective on shares of Globus Medical in a research note on Wednesday. Canaccord Genuity Group upped their price objective on shares of Globus Medical from $79.00 to $85.00 and gave the company a "buy" rating in a research note on Wednesday. Royal Bank of Canada upped their price objective on shares of Globus Medical from $80.00 to $92.00 and gave the company an "outperform" rating in a research note on Wednesday. Wells Fargo & Company upped their price objective on shares of Globus Medical from $78.00 to $88.00 and gave the company an "overweight" rating in a research note on Wednesday. Finally, Truist Financial upped their price target on shares of Globus Medical from $78.00 to $79.00 and gave the company a "hold" rating in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $87.09.

Globus Medical Price Performance

GMED stock traded down $0.46 during midday trading on Thursday, reaching $82.25. The company had a trading volume of 625,216 shares, compared to its average volume of 996,408. Globus Medical has a 1 year low of $43.38 and a 1 year high of $84.87. The company has a market capitalization of $11.14 billion, a P/E ratio of 275.67, a P/E/G ratio of 2.06 and a beta of 1.17. The firm has a 50-day moving average price of $71.92 and a 200-day moving average price of $68.16.

Globus Medical (NYSE:GMED - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The medical device company reported $0.83 EPS for the quarter, topping analysts' consensus estimates of $0.65 by $0.18. Globus Medical had a net margin of 1.82% and a return on equity of 8.70%. The business had revenue of $625.71 million during the quarter, compared to analysts' expectations of $604.69 million. During the same quarter in the previous year, the company earned $0.57 EPS. The business's quarterly revenue was up 63.1% compared to the same quarter last year.

Institutional Trading of Globus Medical

Several institutional investors have recently bought and sold shares of the company. Stephens Inc. AR grew its position in Globus Medical by 3.4% during the 3rd quarter. Stephens Inc. AR now owns 4,229 shares of the medical device company's stock valued at $303,000 after purchasing an additional 138 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Globus Medical by 2.5% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 5,637 shares of the medical device company's stock valued at $403,000 after acquiring an additional 140 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Globus Medical by 15.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,165 shares of the medical device company's stock valued at $80,000 after acquiring an additional 160 shares during the last quarter. Van ECK Associates Corp boosted its holdings in shares of Globus Medical by 0.4% during the 2nd quarter. Van ECK Associates Corp now owns 45,922 shares of the medical device company's stock valued at $3,145,000 after acquiring an additional 183 shares during the last quarter. Finally, Central Pacific Bank Trust Division lifted its position in Globus Medical by 6.2% during the third quarter. Central Pacific Bank Trust Division now owns 3,751 shares of the medical device company's stock valued at $268,000 after purchasing an additional 220 shares during the period. 95.16% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Globus Medical news, Director David D. Davidar sold 30,000 shares of the company's stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $75.04, for a total value of $2,251,200.00. Following the completion of the transaction, the director now directly owns 536,275 shares in the company, valued at approximately $40,242,076. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Globus Medical news, Director David D. Davidar sold 30,000 shares of the company's stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $75.04, for a total value of $2,251,200.00. Following the completion of the transaction, the director now directly owns 536,275 shares in the company, valued at approximately $40,242,076. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ann D. Rhoads sold 15,000 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $70.36, for a total transaction of $1,055,400.00. Following the completion of the transaction, the director now owns 42,884 shares of the company's stock, valued at approximately $3,017,318.24. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 18.54% of the company's stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.